Skip to main content
TARS
NASDAQ Life Sciences

Tarsus Q2 Smashes Estimates, Raises Guidance, and Announces Alkeus Acquisition and $125M Placement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$58.27
Mkt Cap
$2.637B
52W Low
$40.55
52W High
$85.25
52W Position info
44% above low
Off High info
32% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).

Summary

Tarsus reported Q2 2026 XDEMVY sales of $173.9M (+69% YoY), raised full-year guidance to $685-705M, announced the acquisition of Alkeus Pharmaceuticals for its Phase 3 Stargardt disease program, and priced a $125M private placement.

Updates

  1. · SEC 10-Q — Operating cash flow was $36.6M for H1 2026, and the $125M PIPE was priced at $56 per share.


Key Events · Earnings and Guidance · TARS

  • Q2 XDEMVY Sales Surge 69%

    Net product sales reached $173.9M in Q2 2026, up from $102.7M a year ago, driven by higher volume and improved gross-to-net discounts.

  • Full-Year Guidance Raised to $685-705M

    Management lifted 2026 XDEMVY net sales guidance from prior levels, reflecting strong demand and commercial execution.

  • Alkeus Acquisition Adds Phase 3 Retina Asset

    Tarsus agreed to acquire Alkeus Pharmaceuticals, gaining ALK-001, a once-daily oral therapy for Stargardt disease affecting over 36,000 U.S. patients, with a Phase 3 program underway.

  • $125M Private Placement Priced

    The company priced a $125 million private placement with top-tier funds and existing Alkeus investors, strengthening the balance sheet to fund the acquisition and pipeline.


Analysis · TARS · Life Sciences

Tarsus delivered a standout quarter with XDEMVY net sales of $173.9M, up 69% year-over-year, and raised full-year guidance to $685-705M — well above consensus. The company also announced the acquisition of Alkeus Pharmaceuticals, adding a Phase 3 Stargardt disease asset, and priced a $125M private placement. These moves transform the growth narrative: strong commercial execution funds pipeline expansion without balance sheet strain, and the Alkeus deal deepens the retina franchise. The combination of beat-and-raise, strategic M&A, and a well-supported financing makes this a thesis-altering update.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARS was trading at $58.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $77.93 info
Change: +$3.93 (+5%) info
Market Cap: $3.842B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $77.93 info
Change: +$6.69 (+9%) info
Market Cap: $3.842B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $77.93 info
Change: +$7.11 (+10%) info
Market Cap: $3.842B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $77.93 info
Change: -$3.19 (-4%) info
Market Cap: $3.842B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $77.93 info
Change: +$19.66 (+34%) info
Market Cap: $3.842B info